Compare ICCM & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | FGEN |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 35.6M |
| IPO Year | N/A | 2014 |
| Metric | ICCM | FGEN |
|---|---|---|
| Price | $0.71 | $9.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $146.50 |
| AVG Volume (30 Days) | ★ 372.4K | 41.9K |
| Earning Date | 11-19-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | $2,975,000.00 | ★ $8,298,000.00 |
| Revenue This Year | $13.67 | N/A |
| Revenue Next Year | $38.55 | N/A |
| P/E Ratio | ★ N/A | $0.18 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $4.85 |
| 52 Week High | $1.66 | $21.94 |
| Indicator | ICCM | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 59.22 |
| Support Level | $0.58 | $8.50 |
| Resistance Level | $0.68 | $9.32 |
| Average True Range (ATR) | 0.03 | 0.51 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 91.48 | 97.24 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.